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These are the type of controlled drug delivery systems, 
which release the drug in continuous manner by both 
dissolution controlled as well as diffusion controlled 
mechanisms. To control the release of the drugs, which 
are having different solubility properties, the drug is 
dispersed in swellable hydrophilic substances, an 
insoluble matrix of rigid non swellable hydrophobic 
materials or plastic materials.1, 2 
One of the least complicated approaches to the 
manufacture of sustained release dosage forms involves 
the direct compression of blend of drug, retardant material 
and additives to formulate a tablet in which the drug is 
embedded in a matrix of the retardant. Alternatively drug 
and retardant blend may be granulated prior to 
compression. The materials most widely used in preparing 
matrix systems include both hydrophilic and hydrophobic 
polymers. Commonly available hydrophilic polymers 
include Hydroxypropylmethylcellulose (HPMC), 
Hydroxypropylcellulose (HPC), Hydroxyethyl cellulose 
(HEC), Xanthan gum, Sodium alginate, Poly (ethylene 
oxide) and cross-linked homopolymers and copolymers of 
Acrylic acid. It is usually supplied in micronized forms 
because small particle size is critical to the rapid 
formation of gelatinous layer on the tablet surface. 3, 4 
Introduction of matrix tablet as sustained release (SR) has 
given a new break through for novel drug delivery system 
(NDDS) in the field of Pharmaceutical technology. It 
excludes complex production procedures such as coating 
and pelletization during manufacturing and drug release 
rate from the dosage form is controlled mainly by the type 
and proportion of polymer used in the preparations. 
Hydrophilic polymer matrix is widely used for 
formulating an SR dosage form. 5-7 
The major Drawbacks Associated with Conventional 
Dosage Forms are 
 Poor patient compliance, increased chances of missing 
the dose of a drug with short half-life for which 
frequent administration is necessary. 
 The unavoidable fluctuations of drug concentration 
may lead to under medication or over medication. 
 A typical peak-valley plasma concentration-time 
profile is obtained which makes attainment of steady-
state condition difficult. 
 The fluctuations in drug levels may lead to 
precipitation of adverse effects especially of a drug 
with small Therapeutic Index (TI) whenever over 
medication occur. 
 Recently, several advancements in drug delivery 
system have been made to overcome the drawback of 
conventional drug delivery system. These techniques 
are capable of controlling the rate of drug delivery, 
sustaining the duration of therapeutic activity or 
targeting the delivery of drug to a tissue.
8, 9
 
CLASSIFICATION OF MATRIX TABLETS: 
(a) On the Basis of Retardant Material Used:  
Matrix tablets can be divided in to 5 types. 
1. Hydrophobic Matrices (Plastic matrices)
 10
 
The concept of using hydrophobic or inert materials as 
matrix materials was first introduced in 1959. In this 
method of obtaining sustained release from an oral dosage 
form, drug is mixed with an inert or hydrophobic polymer 
and then compressed in to a tablet. Sustained release is 
produced due to the fact that the dissolving drug has 
diffused through a network of channels that exist between 
compacted polymer particles. Examples of materials that 
have been used as inert or hydrophobic matrices include 
polyethylene, polyvinyl chloride, ethyl cellulose and 
acrylate polymers and their copolymers. The rate-
controlling step in these formulations is liquid penetration 
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into the matrix. The possible mechanism of release of 
drug in such type of tablets is diffusion. Such types of 





These matrices prepared by the lipid waxes and related 
materials. Drug release from such matrices occurs through 
both pore diffusion and erosion. Release characteristics 
are therefore more sensitive to digestive fluid composition 
than to totally insoluble polymer matrix. Carnauba wax in 
combination with stearyl alcohol or stearic acid has been 





Hydrophilic polymer matrix systems are widely used in 
oral controlled drug delivery because of their flexibility to 
obtain a desirable drug release profile, cost effectiveness, 
and broad regulatory acceptance. The formulation of the 
drugs in gelatinous capsules or more frequently, in tablets, 
using hydrophilic polymers with high gelling capacities as 
base excipients is of particular interest in the field of 
controlled release. Infect a matrix is defined as well mixed 
composite of one or more drugs with a gelling agent 
(hydrophilic polymer). These systems are called swellable 
controlled release systems. The polymers used in the 
preparation of hydrophilic matrices are divided in to three 
broad groups, 
A. Cellulose derivatives: Methylcellulose 400 and 
4000cPs, Hydroxyethylcellulose, 
Hydroxypropylmethylcellulose (HPMC) 25, 100, 4000 
and 15000cPs; and Sodium carboxymethylcellulose. 
B. Non cellulose natural or semi synthetic polymers: 
Agar-Agar; Carob gum; Alginates; Molasses; 
Polysaccharides of mannose and galactose, Chitosan and 
Modified starches. 





These consist of the polymers which comprised of 
monomers linked to one another through functional 
groups and have unstable linkage in the backbone. They 
are biologically degraded or eroded by enzymes generated 
by surrounding living cells or by nonenzymetic process in 
to oligomers and monomers that can be metabolized or 
excreted. Examples are natural polymers such as proteins 
and polysaccharides; modified natural polymers; synthetic 





These consist of polymers which are obtained from 
various species of seaweeds. Example is Alginic acid 
which is a hydrophilic carbohydrate obtained from species 
of brown seaweeds (Phaephyceae) by the use of dilute 
alkali. 
(b) On the Basis of Porosity of Matrix: 
13-16 
Matrix system can also be classified according to their 
porosity and consequently, Macro porous; Micro porous 
and Nonporous systems can be identified: 
1. Macro porous Systems: 
In such systems the diffusion of drug occurs through pores 
of matrix, which are of size range 0.1 to 1 μm. This pore 
size is larger than diffusant molecule size. 
2. Micro porous System: 
Diffusion in this type of system occurs essentially through 
pores. For micro porous systems, pore size ranges 
between 50 – 200 A°, which is slightly larger than 
diffusant molecules size. 
3. Non-porous System: 
Non-porous systems have no pores and the molecules 
diffuse through the network meshes. In this case, only the 
polymeric phase exists and no pore phase is present. 
 
Figure 1 : Schematic representation of diffusion across 
the Matrix 
EFFECT OF VARIOUS PARAMETERS ON DRUG 
RELEASE
17,18 
Drug release kinetics may be affected by many factors 
such as polymer swelling, polymer erosion, drug 
dissolution/diffusion characteristics, drug distribution 
inside the matrix, drug/polymer ratio and system geometry 
(cylinder, sphere ). 
A. Drug solubility: 
Water solubility of drug and molecular size is another 
important factor which is considered in the release of drug 
from swelling and erosion controlled polymeric matrices. 
For drugs with reasonable aqueous solubility, release of 
water soluble drugs occurs by dissolution in infiltrating 
medium and the release of poorly water soluble drug are 
occurs by both dissolution of drug and dissolution of drug 
particles through erosion of the matrix tablet. 
B. Polymer hydration 
It is important to study polymer hydration/swelling 
process for the maximum number of polymers and 
polymeric combinations. The more important step in 
polymer dissolution include absorption/adsorption of 
water in more accessible places, rupture of polymer-
polymer linkings with the simultaneous forming of water-
polymer linkings, separation of polymeric chains, swelling 
and finally dispersion of polymeric chain in dissolution 
medium. 
C. Polymer diffusivity: 
The diffusion of small molecules in polymer structure is 
energy activated process in which the diffusant molecules 
moves to a successive series of equilibrium position when 
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a sufficient amount of energy of activation for diffusion 
Ed has been acquired by the diffusant is dependent on 
length of polymer chain segment, cross linking and 
crystallinity of polymer. The release of drug may be 
attributed to the mainly two factors- 
 Polymer viscosity: Increasing the molecular weight or 
viscosity of the polymer in the matrix formulation 
increases the gel layer viscosity and thus slows drug 
dissolution. 
 Polymer concentration: An increase in polymer 
concentration causes an increase in the viscosity of gel 
as well as formulation of gel layer with a longer 
diffusional path. This could cause a decrease in the 
effective diffusion coefficient of the drug and therefore 
reduction in drug release. 
D. Thickness of polymer diffusional path: 
The controlled release of a drug from matrix type 
polymeric drug delivery system is essentially governed by 
Fick’s law of diffusion: 
           JD = D dc/dx 
Where, 
       JD = flux of diffusion across a plane surface of unit 
area  
        D = is diffusibility of drug molecule,  
   dc/dx = is concentration gradient of drug molecule 
across a diffusion path with thickness dx. 
E. Thickness of hydrodynamic diffusion layer: 
The drug release profile is a function of the variation in 
thickness of hydrodynamic diffusion layer on the surface 
of matrix type delivery devices. As the thickness of 
hydrodynamic diffusion layer increases, the magnitude of 
drug release value decreases. 
F. Drug loading dose: 
The release kinetics is significantly affected by loading 
dose of drug. The effect of initial drug loading of the 
tablets on the resulting release kinetics is more complex in 
case of poorly water soluble drugs, with increasing initial 
drug loading the relative release rate first decreases and 
then increases, whereas, absolute release rate 
monotonically increases. In case of freely water soluble 
drugs, the porosity of matrix upon drug depletion 
increases with increasing initial drug loading. 
G. Surface area: 
Both the in vitro and in vivo rate of the drug release, are 
observed to be dependent upon surface area of dosage 
form. The release of drug from small tablet is faster than 
large cylindrical tablets. 
H. Effect of diluent: 
The effect of diluent or filler depends upon the nature of 
diluent. Water soluble diluents like lactose cause marked 
increase in drug release rate and release mechanism is also 
shifted towards Fickian diffusion; while insoluble diluents 
like dicalcium phosphate reduce the Fickian diffusion and 
increase the relaxation (erosion) rate of matrix. The reason 
behind this is that water soluble filler in matrices stimulate 
the water penetration in to inner part of matrix, due to 
increase in hydrophilicity of the system, causing rapid 
diffusion of drug, leads to increased drug release rate. 
I. Additives: 
The effect of adding non-polymeric excipients to a 
polymeric matrix has been claimed to produce increase in 
release rate of hydrosoluble active principles. These 
increases in release rate would be marked if the excipients 
are soluble like lactose and less important if the excipients 
are insoluble like tricalcium phosphate.3, 10, 16 
POLYMERS USED IN THE MATRIX
19
 
The polymers most widely used in preparing matrix 
system include both hydrophilic and hydrophobic 
polymers. 
(A) Hydrophilic Polymers:  
Hydroxyl propyl methyl cellulose (HPMC), hydroxyl 
propyl cellulose(HPC), hydroxyl ethyl cellulose (HEC), 
Xanthan gum, Sodium alginate, poly(ethylene oxide), and 
cross linked homopolymers and co-polymers of acrylic 
acid.  
(B) Hydrophobic Polymers:  
This usually includes waxes and water insoluble polymers 
in their formulation.  
(C) Waxes:  
Carnauba wax, bees wax, candelilla wax, micro crystalline 
wax, ozokerite wax, paraffin waxes and low molecular 
weight polyethylene.  
(D) Insoluble polymers: ammoniomethacrylate co-
polymers (Eudragit RL100, PO, RS100, PO), ethyl 
cellulose, cellulose acetate butyrate, cellulose acetate 
propionate and latex dispersion of meth acrylic ester 
copolymers. 
FACTORS AFFECTING DRUG RELEASE FROM 
MATRIX TABLETS
20 
1. Swelling characteristics of polymers  
2. Polymer erosion  
3. Drug loading  
4. Drug solubility  
ADVANTAGES OF MATRIX TABLETS
21 
1. Easy to manufacture.  
2. Versatile and effective  
3. It has low cost.  
4. Can be made to release high molecular weight 
compounds.  
5. Suitable for both non degradable and degradable 
systems.  
6. No danger of dose dumping in case of rupture.  
7. Can be fabricated in a wide range of sizes and shapes.  
DISADVATAGES OF MATRIX TABLETS
22
  
1. The remaining matrix must be removed after the drug 
has been released.  
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2. The drug release rates vary with the square root of time.  
3. Achievement of zero order release is difficult.  
4. Not all drugs can be blended with a given polymeric 
matrix. 
5. Water soluble drugs have a tendency to burst from the 
system. 
6. Poor in vitro – in vivo correlation.  
7. Possibility of dose dumping due to food, physiologic or 
formulation variables. 
8. Retrieval of drug is difficult in case of toxicity, 
poisoning or hypersensitivity reactions.  
9. Reduced potential for dosage adjustment of drugs 
normally administered in varying     strengths.  
10. Stability problems.  
11. Increased cost.  
12. More rapid development of tolerance and counseling.  
13. Need for additional patient education and counseling.  
CRITERIA TO BE MET BY DRUG PROPOSED TO 




a) Desirable half-life. 
b) High therapeutic index 
c) Small dose 
d) Desirable absorption and solubility characteristics. 
e) Desirable absorption window. 
f) First past clearance. 
a) Desirable half-life: 
The half-life of a drug is an index of its residence time in 
the body. If the drug has a short half life (less than 2 
hours), the dosage form may contain a prohibitively large 
quantity of the drug. On the other hand, drug with 
elimination half-life of eight hours or more are sufficiently 
sustained in the body, when administered in conventional 
dosage from, and sustained release drug delivery system is 
generally not necessary in such cases. Ideally, the drug 
should have half-life of three to four hours. 
b) High therapeutic index: 
Drugs with low therapeutic index are unsuitable for 
incorporation in sustained release formulations. If the 
system fails in the body, dose dumping may occur, leading 
to fatalities eg. Digitoxin 
c) Small dose:  
If the dose of a drug in the conventional dosage form is 
high, its suitability as a candidate for sustained release is 
seriously undetermined. This is chiefly because the size of 
a unit dose sustained release formulation would become 
too big, to administer without difficulty. 
d) Desirable absorption and solubility characteristics: 
Absorption of poorly water soluble drug is often 
dissolution rate limited. Incorporating such Compounds 
into sustained release formulations is therefore unrealistic 
and may reduce overall Absorption efficiency. 
e) Desirable absorption window: 
Certain drugs when administered orally are absorbed only 
from a specific part of gastrointestinal tract. This part is 
referred to as the ‘absorption window’. Drugs exhibiting 
an Absorption window like fluorouracil, thiazide diuretics, 
if formulated as sustained release dosage forms are 
unsuitable. 
f) First pass clearance: 
As discussed earlier in disadvantages of sustained delivery 
system, delivery of the drug to the body in desired 
concentrations is seriously hampered in case of drugs 
undergoing extensive hepatic first pass metabolism, when 
administered in sustained release forms. 
DRUG RELEASE FROM MATRIX
25
 
Drug in the outside layer exposed to the bathing solution 
is dissolved first and then diffuses out of the matrix. This 
process continues with the interface between the bathing 
solution and the solid drug moving toward the interior. It 
follows that for this system to be diffusion controlled, the 
rate of dissolution of drug particles within the matrix must 
be much faster than the diffusion rate of dissolved drug 
leaving the matrix. Derivation of the mathematical model 
to describe this system involves the following 
assumptions:  
a) A pseudo-steady state is maintained during drug 
release;  
b) The diameter of the drug particles is less than the 
average distance of drug diffusion through the matrix;  
c) The bathing solution provides sink conditions at all 
times.  
The release behaviour for the system can be 
mathematically described by the following equation:  
 = Co. Dh - Cs/2----- (1)  
Where, 
           DM = Change in the amount of drug released per 
unit area  
           Dh = Change in the thickness of the zone of matrix 
that has been depleted of drug  
           Co = Total amount of drug in a unit volume of 
matrix  
           Cs = Saturated concentration of the drug within the 
matrix. 
Additionally, according to diffusion theory:  
     dM = (Dm. Cs / h).Dt----- (2)  
Where,   
            dm = Diffusion coefficient in the matrix.  
                h = Thickness of the drug-depleted matrix  
              Dt = Change in time By combining equation 1 
and equation 2 and integrating:  
     M = [Cs. Dm. (2Co−Cs). t] ½------ (3)  
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When the amount of drug is in excess of the saturation 
concentration, then:  
     M = [2Cs. Dm. Co. t] ½----- (4)  
Equation 3 and equation 4 relate the amount of drug 
release to the square-root of time. Therefore, if a system is 
predominantly diffusion controlled, then it is expected that 
a plot of the drug release vs. square root of time will result 
in a straight line. Drug release from a porous monolithic 
matrix involves the simultaneous penetration of 
surrounding liquid, dissolution of drug and leaching out of 
the drug through tortuous interstitial channels and pores. 
The volume and length of the openings must be accounted 
for in the drug release from a porous or granular matrix:  
    M = [Ds.Ca.p/T. (2Co – p.Ca) t] ½------ (5)  
Where,  
              p = Porosity of the matrix  
              t = Tortuosity  
           Ca = solubility of the drug in the release medium  
           Ds = Diffusion coefficient in the release medium.  
            T = Diffusion path length for pseudo steady state, 
the equation can be written as:  
          M = [2D.Ca .Co (p/T) t] ½------ (6)  
The total porosity of the matrix can be calculated with the 
following equation:  
    p = pa + Ca/ ρ + Cex / ρex------ (7)  
Where, 
             p = Porosity  
             ρ = Drug density  
            pa = Porosity due to air pockets in the matrix  
            ρex = Density of the water soluble excipients  
            Cex = Concentration of water soluble excipients 
For the purpose of data treatment, equation 7 can be 
reduced to:  
       M = k. t ½------ (8)  
Where k is a constant, so that the amount of drug released 
versus the square root of time will be linear, if the release 
of drug from matrix is diffusion-controlled. 
 
           Figure 2: Drug arrangement in matrix tablet 
 
                                 Figure 3: Scheme of the 
hydrophilic matrix after entry of the dissolution 
medium 
 [A] The swelling front. With the entry of water into the 
matrix, the polymer passes from the crystalline state to a 
hydrated or gelified state. 
[B] The erosion front or dissolution front: This separates 
the gelified zone from the matrix of the solvent. 
[C] Diffusion front (solid drug–drug solution boundary): 
This is located between the swelling and erosion fronts 
and it separates the zone of the gelified matrix containing 
the drug dissolved in the medium from the zone of the 
matrix containing the undissolved solid drug. 




Before marketing a sustained release product, it is must to 
assure the strength, safety, stability and reliability of a 
product by forming in-vitro and in vivo analysis and 
correlation between the two. Various authors have 
discussed the evaluating parameters and procedures for 
sustained release formulations. 
1. In-Vitro Methods 
   These are:- 
a. Beaker method 
b. Rotating disc method 
c. Rotating Bottle method 
d. Rotating Basket method 
e. Stationary Basket Method 
f. Oscillating tube method 
g. Dialysis method 
h. USP dissolution method. 
2. In–Vivo Methods 
Once the satisfactory in-vitro profile is achieved, it 
becomes necessary to conduct in-vivo evaluation and 
establish in-vitro in-vivo correlation. The various in-vivo 
evaluation methods are:- 
a. Clinical response 
b. Blood level data 
c. Urinary excretion studies 
d. Nutritional studies. 
e. Toxicity studies 
f. Radioactive tracer techniques 
3. Stability Studies: 
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Adequate stability data of the drug and its dosage form is 
essential to ensure the strength, safety, identity, quality, 
purity and in-vitro in-vivo release rates that they claim to 
have at the time of use. A sustained release product should 
release a predetermined amount of the drug at specified 
time intervals, which should not change on storage. Any 
considerable deviation from the appropriate release would 
render the sustained release product useless. The in-vitro 
and in-vivo release rates of sustained release product may 
be altered by atmospheric or accelerated conditions such 
as temperature & humidity. The stability programmes of a 
sustained release product include storage at both nominal 
and accelerated conditions such as temperature & 
humidity to ensure that the product will withstand these 
conditions. 
4. In vitro- In vivo Correlations:
 24,25 
The requirement of establishing good in-vitro invivo 
correlation in the development of sustained release 
delivery systems is self-evident. To make a meaningful in-
vitro in-vivo correlation one has to consider not only the 
pharmaceutical aspect of sustained release drug delivery 
system but also the biopharmaceutics and 
pharmacokinetics of the therapeutic agent in the body 
after its release from the drug delivery system and also the 
pharmacodynamics of therapeutic agent at the site of drug 
action. A simple in vitro-in vitro relationship can be 
established by conducting in-vitro and in-vivo evaluations 
of a potential drug delivery system simultaneously to 
study and compare the mechanism and rate profiles of 
sustained drug release. When the in-vivo drug release 
mechanism is proven to be in good agreement with that 
observed in the in-vitro drug release studies, then in-vitro 
in-vivo correlation factor is derived. For capsule type drug 
delivery system the factor can be represented as: 
(Q/t) In-vivo 
Q= (Q/t) In-vitro 
Where, 
 Q/t = Rate of release 
‘Q’ values are dependent profiles of drug delivery 
systems. upon the sites of administration   and 
environmental conditions to which the animals are 
exposed during treatment (study). 
The above relationship can be used for optimization of 
sustained release Levy has classified In-vivo-In-vitro 
correlation in to: 
a] Pharmacological correlations based on clinical 
observations; 
b] Semi-quantitative correlations based on blood levels or 
urinary excretion data; 
c] Quantitative correlation arising from absorption 
kinetics. While most of the published correlations are of 
semi-quantitative nature, the most valuable are those 
based on absorption kinetics. 
5. Bioavailability Testing: 
Bioavailability is generally defined as the rate and extent 
of absorption of unchanged drug from its site of 
application to the general circulation. Bioavailability is 
defined in terms of a specific drug moiety, usually active 
therapeutic entity, which may be the unchanged drug or as 
with prodrug, for instance, a metabolite. In contrast, the 
term "absorption" often refers to net transport of drug 
related mass from its site of application into the body. 
Hence, a compound may be completely absorbed but only 
partially bioavailable as would occur, when low 
bioavailability is caused by incomplete absorption. 
Pharmaceutical optimization of the dosage form may be 
warranted to improve absorption characteristics of the 
drug and thereby also its bioavailability. Bioavailability 
studies are ordinarily single dose comparisons of tested 
drug product in normal adults in a fasting state. A 
crossover design, in which all subjects receive both, the 
product and reference material on different days is 
preferred. Guidelines for clinical testing have been 
published for multiple dose studies. Correlation of 
pharmacological activity or clinical evidence of 
therapeutic effectiveness with bioavailability may be 
necessary to validate the single significance of sustained 
release claims. While single dose studies are usually 
sufficient to establish the validity of sustained release 
dosage form design; multiple dose studies are required to 
establish optimum dosing regimen. They are also required 
when difference may exist in the rate but not the extent of 
absorption. When there is excessive subject-to subject 
variation or when the observed sblood levels after a single 
dose are too low to be measured accurately. A sufficient 
number of doses must be administered to attain steady 
state blood levels. According to an extensive study of 
sustained release Theophylline products; for example, 
encapsulated forms showed less peaking during multiple 
dosing and therefore better control of blood level within 
the desired limits. 
CONCLUSION 
By the above discussion, it can be easily concluded that 
sustained-release formulation are helpful in increasing the 
efficiency of the dose as well as they are also improving 
the patient’s compatibility matrix forming polymers can 
be successfully used to prepare Matrix tablets, releasing 
drug in a controlled manner. Preparatory procedures easily 
allow adaptation of release kinetics to delivery needs. This 
suitability of matrix forming polymers, to various drug 
delivery systems preparation confirms the importance of 
these specialized excipients in pharmaceutical application. 
They represent the choice solution for many oral delivery 
problems like fluctuating drug plasma levels, low 
bioavailability, more frequent dose administration etc. So 
matrix tablets can overcome the above problems of 
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